(Q37959880)

25 August 2017

title

What happened to anti-CD33 therapy for acute myeloid leukemia? (English)

1 reference

25 August 2017

1 reference

Joseph G Jurcic

1

1 reference

25 August 2017

publication date

1 March 2012

1 reference

Current hematologic malignancy reports

25 August 2017

published in

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

65-73

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-011-0103-0

25 August 2017

exact match

0 references

cites work

Heterogeneity of clonogenic cells in acute myeloblastic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

The human high affinity IgG receptor (Fc gamma RI) signals through the immunoreceptor tyrosine-based activation motif (ITAM) of the gamma chain of Fc epsilon RI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Tumor therapy with targeted atomic nanogenerators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0103-0

In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin

21 January 2018

1 reference

12 December 2020

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

1 reference

12 December 2020

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients

1 reference

12 December 2020

Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

1 reference

12 December 2020

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

12 December 2020

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

12 December 2020

Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)

1 reference

12 December 2020

Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.

1 reference

12 December 2020

Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia

1 reference

12 December 2020

The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors

1 reference

12 December 2020

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

12 December 2020

A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity

1 reference

12 December 2020

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

1 reference

12 December 2020

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

1 reference

12 December 2020

Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies

1 reference

12 December 2020

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

12 December 2020

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia

1 reference

12 December 2020

Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model

1 reference

12 December 2020

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial

1 reference

12 December 2020

Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.

1 reference

12 December 2020

Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC

1 reference

12 December 2020

10.1007/S11899-011-0103-0

Identifiers

DOI

1 reference

release_no2byxnzhrbczms65gxegjkzy4

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/no2byxnzhrbczms65gxegjkzy4

24 November 2022

mapped directly with Wikidata item

1 reference